430 related articles for article (PubMed ID: 30732506)
1. Review of the efficacy of AST-120 (KREMEZIN
Asai M; Kumakura S; Kikuchi M
Ren Fail; 2019 Nov; 41(1):47-56. PubMed ID: 30732506
[TBL] [Abstract][Full Text] [Related]
2. Risk factors for progression of chronic kidney disease in the EPPIC trials and the effect of AST-120.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Kikuchi M; Shobu Y
Clin Exp Nephrol; 2018 Apr; 22(2):299-308. PubMed ID: 28741050
[TBL] [Abstract][Full Text] [Related]
3. Randomized Placebo-Controlled EPPIC Trials of AST-120 in CKD.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Arita K; Kato A; Shimizu M
J Am Soc Nephrol; 2015 Jul; 26(7):1732-46. PubMed ID: 25349205
[TBL] [Abstract][Full Text] [Related]
4. The effects of AST-120 on chronic kidney disease progression in the United States of America: a post hoc subgroup analysis of randomized controlled trials.
Schulman G; Berl T; Beck GJ; Remuzzi G; Ritz E; Shimizu M; Shobu Y; Kikuchi M
BMC Nephrol; 2016 Sep; 17(1):141. PubMed ID: 27716149
[TBL] [Abstract][Full Text] [Related]
5. Effect of AST-120 in Chronic Kidney Disease Treatment: Still a Controversy?
Yamaguchi J; Tanaka T; Inagi R
Nephron; 2017; 135(3):201-206. PubMed ID: 27960172
[TBL] [Abstract][Full Text] [Related]
6. Impacts of Indoxyl Sulfate and p-Cresol Sulfate on Chronic Kidney Disease and Mitigating Effects of AST-120.
Liu WC; Tomino Y; Lu KC
Toxins (Basel); 2018 Sep; 10(9):. PubMed ID: 30208594
[TBL] [Abstract][Full Text] [Related]
7. Comparison of Different Types of Oral Adsorbent Therapy in Patients with Chronic Kidney Disease: A Multicenter, Randomized, Phase IV Clinical Trial.
Kee YK; Han SY; Kang DH; Noh JW; Jeong KH; Kim GH; Kim YW; Kim BS
Yonsei Med J; 2021 Jan; 62(1):41-49. PubMed ID: 33381933
[TBL] [Abstract][Full Text] [Related]
8. The role of carbon adsorbent in the conservative management of chronic kidney disease.
Niwa T
Panminerva Med; 2017 Jun; 59(2):139-148. PubMed ID: 27990791
[TBL] [Abstract][Full Text] [Related]
9. A Randomized, Controlled Trial of Oral Intestinal Sorbent AST-120 on Renal Function Deterioration in Patients with Advanced Renal Dysfunction.
Cha RH; Kang SW; Park CW; Cha DR; Na KY; Kim SG; Yoon SA; Han SY; Chang JH; Park SK; Lim CS; Kim YS
Clin J Am Soc Nephrol; 2016 Apr; 11(4):559-67. PubMed ID: 26912554
[TBL] [Abstract][Full Text] [Related]
10. Uremic toxicity of indoxyl sulfate.
Niwa T
Nagoya J Med Sci; 2010 Feb; 72(1-2):1-11. PubMed ID: 20229698
[TBL] [Abstract][Full Text] [Related]
11. An oral adsorbent, AST-120, combined with a low-protein diet and RAS blocker, for chronic kidney disease.
Yorioka N; Kiribayashi K; Naito T; Ogata S; Yokoyama Y; Kyuden Y; Ogawa T; Wada K; Hayashi K; Hirabayashi A
J Nephrol; 2008; 21(2):213-20. PubMed ID: 18446716
[TBL] [Abstract][Full Text] [Related]
12. Impact of the Oral Adsorbent AST-120 on Organ-Specific Accumulation of Uremic Toxins: LC-MS/MS and MS Imaging Techniques.
Sato E; Saigusa D; Mishima E; Uchida T; Miura D; Morikawa-Ichinose T; Kisu K; Sekimoto A; Saito R; Oe Y; Matsumoto Y; Tomioka Y; Mori T; Takahashi N; Sato H; Abe T; Niwa T; Ito S
Toxins (Basel); 2017 Dec; 10(1):. PubMed ID: 29283413
[TBL] [Abstract][Full Text] [Related]
13. Continuous Reduction of Protein-Bound Uraemic Toxins with Improved Oxidative Stress by Using the Oral Charcoal Adsorbent AST-120 in Haemodialysis Patients.
Yamamoto S; Kazama JJ; Omori K; Matsuo K; Takahashi Y; Kawamura K; Matsuto T; Watanabe H; Maruyama T; Narita I
Sci Rep; 2015 Sep; 5():14381. PubMed ID: 26395517
[TBL] [Abstract][Full Text] [Related]
14. AST-120 for the management of progression of chronic kidney disease.
Schulman G; Vanholder R; Niwa T
Int J Nephrol Renovasc Dis; 2014; 7():49-56. PubMed ID: 24501542
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic effects of long-term administration of an oral adsorbent in patients with chronic renal failure: two-year study.
Takahashi N; Kawaguchi T; Suzuki T
Int J Urol; 2005 Jan; 12(1):7-11. PubMed ID: 15661048
[TBL] [Abstract][Full Text] [Related]
16. Effects of AST-120 on blood concentrations of protein-bound uremic toxins and biomarkers of cardiovascular risk in chronic dialysis patients.
Lee CT; Hsu CY; Tain YL; Ng HY; Cheng BC; Yang CC; Wu CH; Chiou TT; Lee YT; Liao SC
Blood Purif; 2014; 37(1):76-83. PubMed ID: 24576840
[TBL] [Abstract][Full Text] [Related]
17. Oral adsorbent AST-120 potentiates the effect of erythropoietin-stimulating agents on Stage 5 chronic kidney disease patients: a randomized crossover study.
Wu IW; Hsu KH; Sun CY; Tsai CJ; Wu MS; Lee CC
Nephrol Dial Transplant; 2014 Sep; 29(9):1719-27. PubMed ID: 24714415
[TBL] [Abstract][Full Text] [Related]
18. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
[TBL] [Abstract][Full Text] [Related]
19. Preventive effects of an oral sorbent on nephropathy in rats.
Aoyama I; Miyazaki T; Niwa T
Miner Electrolyte Metab; 1999; 25(4-6):365-72. PubMed ID: 10681668
[TBL] [Abstract][Full Text] [Related]
20. An oral adsorbent, AST-120, suppresses oxidative stress in uremic rats.
Nakagawa N; Hasebe N; Sumitomo K; Fujino T; Fukuzawa J; Hirayama T; Kikuchi K
Am J Nephrol; 2006; 26(5):455-61. PubMed ID: 17057375
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
